Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells

Song,Zhou; Wei,Bo; Lu,Canrong; Huang,Xiaohui; Li,Peiyu; Chen,Lin

doi:10.3892/mmr.2017.6205

Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells

Authors:
- Zhou Song
- Bo Wei
- Canrong Lu
- Xiaohui Huang
- Peiyu Li
- Lin Chen
View Affiliations

Affiliations: Department of General Surgery, General Hospital of Chinese PLA, Beijing 100853, P.R. China
Published online on: February 15, 2017 https://doi.org/10.3892/mmr.2017.6205
Pages: 1909-1915

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The traditional anti-diabetic drug, metformin, has been found to have anticancer effects. The Sonic hedgehog (Shh) signaling pathway is involved in the on cogenesis of gastric cancer. The aim of the present study was to investigate whether metformin has an effect on the Shh signaling pathway in gastric cancer cells. HGC‑27 and MKN‑45 human gastric cancer cells were treated with metformin at different concentrations and for different durations. Subsequently the mRNA and protein levels of Shh, Smoothened (SMO), and Glioma‑associated oncogene (Gli)‑1, Gli‑2 and Gli‑3 were examined using western blot and reverse transcription‑quantitative polymerase chain reaction analyses. RNA interference was used to detect whether the effects of metformin treatment on the Shh signaling pathway were dependent on AMP‑activated protein kinase (AMPK). The results revealed that the protein and mRNA levels of Shh and Gli‑1 were decreased by metformin treatment in the two cell lines in a dose‑ and time‑dependent manner. Metformin also significantly inhibited the gene and protein expression levels of SMO, Gli‑2 and Gli‑3. The small interfering RNA‑induced depletion of AMPK reversed the suppressive effect of metformin on recombinant human Shh‑induced expression of Gli‑1 in HGC‑27 gastric cancer cells. Therefore, metformin inhibited the Shh signaling pathway in the gastric cancer cell lines and the inhibitory effect of metformin on the Shh pathway was AMPK-dependent.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Nagini S: Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
4	Micic D, Cvijovic G, Trajkovic V, Duntas LH and Polovina S: Metformin: Its emerging role in oncology. Hormones (Athens). 10:5–15. 2011. View Article : Google Scholar : PubMed/NCBI
5	Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
6	Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ, Lee YJ, Lee EK, Kook MC, Kim CG, Ryu KW and Kim YW: Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: A nationwide cohort study. Aliment Pharmacol Ther. 39:854–63. 2014. View Article : Google Scholar : PubMed/NCBI
8	Vallianou NG, Evangelopoulos A and Kazazis C: Metformin and cancer. Rev Diabet Stud. 10:228–235. 2013. View Article : Google Scholar : PubMed/NCBI
9	Varjosalo M and Taipale J: Hedgehog signaling. J Cell Sci. 120:3–6. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ingham PW: Hedgehog signaling. Cold Spring Harb Perspect Biol. 4(pii): a0112212012.PubMed/NCBI
11	di Magliano M Pasca and Hebrok M: Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 3:903–911. 2003. View Article : Google Scholar : PubMed/NCBI
12	Suzuki H, Minegishi Y, Nomoto Y, Ota T, Masaoka T, van den Brink GR and Hibi T: Down-regulation of a morphogen (sonic hedgehog) gradient in the gastric epithelium of helicobacter pylori-infected mongolian gerbils. J Pathol. 206:186–197. 2005. View Article : Google Scholar : PubMed/NCBI
13	Berman DM, Karhadkar SS, Maitra A, De Oca R Montes, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, et al: Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
14	Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H and Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis. 26:1698–1705. 2005. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Alexander GC, Sehgal NL, Moloney RM and Stafford RS: National trends in treatment of type 2 diabetes mellitus, 1994–2007. Arch Intern Med. 168:2088–2094. 2008. View Article : Google Scholar : PubMed/NCBI
17	Corte CM Della, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, et al: Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget. 7:4265–4278. 2016.PubMed/NCBI
18	Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, Qiu B, Li Y, Guo L, Wu M, et al: Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 19:5372–5380. 2013. View Article : Google Scholar : PubMed/NCBI
19	Sinnett-Smith J, Kisfalvi K, Kui R and Rozengurt E: Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun. 430:352–357. 2013. View Article : Google Scholar : PubMed/NCBI
20	Rozengurt E, Sinnett-Smith J and Kisfalvi K: Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 16:2505–2511. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, Duran C, Selimoglu H, Erturk E, Tuncel E and Imamoglu S: The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract. 81:56–60. 2008. View Article : Google Scholar : PubMed/NCBI
22	Nakamura M, Ogo A, Yamura M, Yamaguchi Y and Nakashima H: Metformin suppresses sonic hedgehog expression in pancreatic cancer cells. Anticancer Res. 34:1765–1769. 2014.PubMed/NCBI
23	Ingham PW and McMahon AP: Hedgehog signaling in animal development: Paradigms and principles. Genes Dev. 15:3059–3087. 2001. View Article : Google Scholar : PubMed/NCBI
24	Lee J, Platt KA, Censullo P and i Altaba A Ruiz: Gli1 is a target of Sonic hedgehog that induces ventral neural tube development. Development. 124:2537–2552. 1997.PubMed/NCBI